OS Therapies announces $6M private placement; OST-HER2 Phase 2b data in Jan 2025

OS Therapies Inc

Gross proceeds of $6M from sale of 1.5M units at $4.00/unit; each unit = 1 share Series A convertible preferred + 1 warrant.
Initial conversion price $4.00, warrant exercise price $4.40; prices subject to reset with floor of $1.00 and ceiling $4.00.
Proceeds to fund working capital and support commercialization of OST-HER2 for recurrent metastatic osteosarcoma.
Phase 2b trial data for OST-HER2 expected during week of JP Morgan Healthcare Conference in January 2025.
95% of investment from pre-IPO and/or IPO investors; $6M provides cash runway into 2026.

item 1.01 item 3.02 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.